GlobeNewsWire
14 Jun 2026, 18:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Long-term data from PATHFNDR-1 and PATHFNDR-2 trials show PALSONIFY maintains durable IGF-1 control and stable symptoms for up to two years. — Consistent long-term efficacy and safety data for a launched product reduce clinical risk and support sustained market adoption.
+0.60PALSONIFY demonstrated the ability to maintain or reduce pituitary tumor volumes in patients for up to 48 weeks. — Tumor stabilization/reduction is a critical secondary clinical endpoint that enhances the drug's competitive profile against existing therapies.
+0.40Combination therapy of PALSONIFY and cabergoline showed improved biochemical control in the ACROBAT Advance study. — Expanding the use case to combination therapy potentially increases the addressable patient population and improves clinical outcomes.
+0.30Continue reading
6 related stories
Top 2 movers · tap to explore
The drug was well-tolerated with no new safety signals identified in the pooled open-label extension population. — The absence of new safety concerns in long-term data removes a major potential hurdle for long-term commercial success.
+0.20Which stocks this story touches
The company presented positive long-term clinical data showing that PALSONIFY provides durable and consistent control of acromegaly.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
